The role of dolutegravir in antiretroviral therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | HU Revista (Online) |
Texto Completo: | https://periodicos.ufjf.br/index.php/hurevista/article/view/13945 |
Resumo: | Integrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations. |
id |
UFJF-8_c51f11a692c700fce2e47a620c0c51c1 |
---|---|
oai_identifier_str |
oai:periodicos.ufjf.br:article/13945 |
network_acronym_str |
UFJF-8 |
network_name_str |
HU Revista (Online) |
repository_id_str |
|
spelling |
The role of dolutegravir in antiretroviral therapyO papel do dolutegravir na terapia antiretroviralHIVHigh Activity Antiretroviral TherapyAcquired Immunodeficiency SyndromeViral LoadDolutegravirHIVTerapia Antirretroviral de Alta AtividadeSíndrome de Imunodeficiência AdquiridaCarga ViralDolutegravirIntegrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations.Os inibidores da integrase são a mais nova classe de antirretroviral aprovada, que agem impedindo a incorporação do DNA do HIV no genoma do linfócito T CD4+ (LTCD4+) do hospedeiro, limitando a propagação do vírus. O Dolutegravir e o inibidor da integrase mais moderno e como os demais inibidores apresenta de alta performance, boa tolerância; alta barreira genética para mutações de resistência, além de apresentar eficácia em pacientes já submetidos a tratamento antirretroviral anterior. Neste contexto o presente estudo trata-se de um estudo de revisão bibliográfica realizada de janeiro a junho de 2018, de artigos científicos de artigos científicos que abordam aspectos exclusivos do dolutegravir na terapia antirretroviral em comparação com outros esquemas terapêuticos. Concluindo que o tratamento com dolutegravir apresenta como principais vantagens à rápida supressão virológica; boa tolerância e alta barreira genética para mutações de resistência.Editora UFJF2019-06-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtRevLitapplication/pdfhttps://periodicos.ufjf.br/index.php/hurevista/article/view/1394510.34019/1982-8047.2018.v44.13945HU Revista; v. 44 n. 3 (2018): Doenças Infecciosas: epidemiologia, prevenção e controle; 379 - 3851982-80470103-3123reponame:HU Revista (Online)instname:Universidade Federal de Juiz de Fora (UFJF)instacron:UFJFporhttps://periodicos.ufjf.br/index.php/hurevista/article/view/13945/18769Vieira, Tamyres dos SantosVieira, Isabela dos SantosBresser, MatheusMoura, Letícia Coutinho LopesMoura, Marcos de Assisinfo:eu-repo/semantics/openAccess2019-07-19T03:00:20Zoai:periodicos.ufjf.br:article/13945Revistahttps://periodicos.ufjf.br/index.php/hurevistaPUBhttps://periodicos.ufjf.br/index.php/hurevista/oairevista.hurevista@ufjf.edu.br1982-80470103-3123opendoar:2019-07-19T03:00:20HU Revista (Online) - Universidade Federal de Juiz de Fora (UFJF)false |
dc.title.none.fl_str_mv |
The role of dolutegravir in antiretroviral therapy O papel do dolutegravir na terapia antiretroviral |
title |
The role of dolutegravir in antiretroviral therapy |
spellingShingle |
The role of dolutegravir in antiretroviral therapy Vieira, Tamyres dos Santos HIV High Activity Antiretroviral Therapy Acquired Immunodeficiency Syndrome Viral Load Dolutegravir HIV Terapia Antirretroviral de Alta Atividade Síndrome de Imunodeficiência Adquirida Carga Viral Dolutegravir |
title_short |
The role of dolutegravir in antiretroviral therapy |
title_full |
The role of dolutegravir in antiretroviral therapy |
title_fullStr |
The role of dolutegravir in antiretroviral therapy |
title_full_unstemmed |
The role of dolutegravir in antiretroviral therapy |
title_sort |
The role of dolutegravir in antiretroviral therapy |
author |
Vieira, Tamyres dos Santos |
author_facet |
Vieira, Tamyres dos Santos Vieira, Isabela dos Santos Bresser, Matheus Moura, Letícia Coutinho Lopes Moura, Marcos de Assis |
author_role |
author |
author2 |
Vieira, Isabela dos Santos Bresser, Matheus Moura, Letícia Coutinho Lopes Moura, Marcos de Assis |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Vieira, Tamyres dos Santos Vieira, Isabela dos Santos Bresser, Matheus Moura, Letícia Coutinho Lopes Moura, Marcos de Assis |
dc.subject.por.fl_str_mv |
HIV High Activity Antiretroviral Therapy Acquired Immunodeficiency Syndrome Viral Load Dolutegravir HIV Terapia Antirretroviral de Alta Atividade Síndrome de Imunodeficiência Adquirida Carga Viral Dolutegravir |
topic |
HIV High Activity Antiretroviral Therapy Acquired Immunodeficiency Syndrome Viral Load Dolutegravir HIV Terapia Antirretroviral de Alta Atividade Síndrome de Imunodeficiência Adquirida Carga Viral Dolutegravir |
description |
Integrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-06-21 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion ArtRevLit |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://periodicos.ufjf.br/index.php/hurevista/article/view/13945 10.34019/1982-8047.2018.v44.13945 |
url |
https://periodicos.ufjf.br/index.php/hurevista/article/view/13945 |
identifier_str_mv |
10.34019/1982-8047.2018.v44.13945 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://periodicos.ufjf.br/index.php/hurevista/article/view/13945/18769 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Editora UFJF |
publisher.none.fl_str_mv |
Editora UFJF |
dc.source.none.fl_str_mv |
HU Revista; v. 44 n. 3 (2018): Doenças Infecciosas: epidemiologia, prevenção e controle; 379 - 385 1982-8047 0103-3123 reponame:HU Revista (Online) instname:Universidade Federal de Juiz de Fora (UFJF) instacron:UFJF |
instname_str |
Universidade Federal de Juiz de Fora (UFJF) |
instacron_str |
UFJF |
institution |
UFJF |
reponame_str |
HU Revista (Online) |
collection |
HU Revista (Online) |
repository.name.fl_str_mv |
HU Revista (Online) - Universidade Federal de Juiz de Fora (UFJF) |
repository.mail.fl_str_mv |
revista.hurevista@ufjf.edu.br |
_version_ |
1796798242506145792 |